



# Sterne Kessler Goldstein Fox

ATTORNEYS AT LAW



Robert Greene Sterne  
Edward J. Kessler  
Jorge A. Goldstein  
David K.S. Cornwell  
Robert W. Esmond  
Tracy-Gene G. Durkin  
Michele A. Cimbala  
Michael B. Ray  
Robert E. Sokohl  
Eric K. Sterne  
Michael Q. Lee  
Steven R. Ludwig  
John M. Covert  
Linda E. Alcorn  
Robert C. Millonig  
Lawrence B. Bugalsky  
Donald J. Featherstone  
Michael V. Messinger

Judith U. Kim  
Timothy J. Shea, Jr.  
Patrick E. Geiger  
Jeffrey T. Helvey  
Heidi L. Kraus  
Crystal D. Sayles  
Edward W. Yee  
Albert L. Ferro\*  
Donald R. Banowitz  
Peter A. Jackman  
Molly A. McCall  
Teresa U. Medler  
Jeffrey S. Weaver  
Kendrick P. Patterson  
Vincent L. Capuano  
Albert J. Fusillo II\*  
Elabora Ellison Floyd  
W. Russell Swindell

Thomas C. Fiala  
Brian J. Del Buono  
Virgil Lee Beaston\*  
Reginald D. Lucas\*  
Kimberly N. Reddick  
Theodore A. Wood  
Elizabeth J. Haanes  
Bruce E. Chalker  
Joseph S. Ostroff  
Frank R. Cottingham\*  
Christine M. Lhuillier  
Rae Lynn Prengaman\*  
Jane Shereshenovich\*  
Lawrence J. Carroll\*  
George S. Bardmesser

Registered Patent Agents\*  
Karen R. Markowicz  
Andrea J. Kamage  
Nancy J. Leith  
Joseph M. Conrad III  
Ann E. Summerfield  
Helene C. Carlson  
Gaby L. Longsworth  
Matthew J. Dowd  
Aaron L. Schwartz  
Angelique G. Uy  
Boris A. Matvenko  
Mary B. Jung  
Katrina Y. Pei  
Bryan L. Shelton  
Jason D. Eisenberg  
John J. Figueroa

Senior Counsel  
Samuel L. Fox  
Kenneth C. Bass III  
Lisa A. Dunner

\*Admitted only in Maryland  
\*Admitted only in Virginia  
\*Admitted only in Texas  
\*Practice Limited to Federal Agencies

July 18, 2002

**WRITER'S DIRECT NUMBER:**  
(202) 371-2544  
**INTERNET ADDRESS:**  
MCIMBALA@SKGF.COM

Commissioner for Patents  
Washington, D.C. 20231

Art Unit 1645

Re: U.S. Utility Patent Application  
Appl. No. 09/903,508; Filed: July 13, 2001  
For: Transformation Systems for Flavinogenic Yeast  
Inventors: Abbas *et al.*  
Our Ref: 1533.0830003/MAC/RGM

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement;
2. A listing of the cited documents on form PTO-1449 (16 pages); and
3. Copies of the cited documents (AA1-AA5;AL1-AN1; and AR1-AT16); and
4. Return Postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Michele A. Cimbala  
Attorney for Applicants  
Registration No. 33,851

MAC/RGM:krm  
Enclosures

SKGF\_DC1:34844.1

1645



THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

|   |                                    |
|---|------------------------------------|
| ABBAS <i>et al.</i>                                   | Art Unit: 1645                     |
| Appl. No. 09/903,508                                  | Examiner: <i>To Be Assigned</i>    |
| Filed: July 13, 2001                                  | Atty. Docket: 1533.0830003/MAC/RGM |
| For: Transformation Systems for<br>Flavinogenic Yeast |                                    |

#11

**Information Disclosure Statement**

Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

In accordance with 37 C.F.R. § 1.98(a)(3), Applicants' undersigned representative submits the following, in regard to non-English language documents AL1, AN1 and AR15 cited on Form PTO 1449:

Document AL1, WO 95/26406, is in a foreign language. AL1 is believed to disclose the DNA sequences corresponding to six genes for riboflavin biosynthesis from *Ashbya gossypii*. An English language abstract of document AL1 is attached as document AS3.

Document AN1, WO 99/61623, is in a foreign language. AN1 is believed to disclose the DNA sequences corresponding to three genes for riboflavin synthesis from *Ashbya gossypii* and a method for increasing riboflavin production in *Ashbya gossypii*. An English language abstract of document AN1 is attached as document AR3.

Document AR4 is in a foreign language. Document AR4 is believed to disclose a thermostable riboflavin kinase in *Pichia guilliermondii* yeast. An English language abstract appears at the end of the article.

Document AS7 is in a foreign language. Document AS7 is believed to disclose the cloning of the *Pichia guilliermondii* riboflavin synthase gene. An English language abstract appears at the end of the article.

Document AS8 is in a foreign language. Document AS8 is believed to disclose transformation of *Hansenula polymorpha*, *Pichia guilliermondii* and *Williopsis saturnus* by a plasmid containing the *S. cerevisiae* ADE2 gene. An English language abstract appears at the end of the article.

Document AT10 is in a foreign language. Document AT10 is believed to disclose a flavinogenous mutant of the yeast *Pichia guilliermondii* with damaged transport of iron. An English language abstract appears at the end of the article.

Document AT11 is in a foreign language. Document AT11 is believed to disclose detection of cryptic riboflavin permease in *Pichia guilliermondii* yeast. An English language abstract appears at the end of the article.

Document AR12 is in a foreign language. Document AR12 is believed to disclose the effect of glucose and its derivatives on systems of riboflavin uptake and excretion in *Pichia guilliermondii* yeast. An English language abstract appears at the end of the article.

Document AS12 is in a foreign language. Document AS12 is believed to disclose inhibition of alkaline phosphatase I of *Pichia guilliermondii* yeast *in vitro* and *in vivo*. An English language abstract appears at the end of the article.

Document AT14 is in a foreign language. Document AT14 is believed to disclose the development of cloning and expression transformation systems for nonconventional yeasts. An English language abstract appears at the end of the article.

Document AR15 is in a foreign language. AR15 is believed to disclose methods for genetically transforming the flavinogenic yeasts *Pichia guilliermondii* and *Candida famata*. An English translation of document AR15 is attached as document AS15.

Document AS16 is in a foreign language. Document AS16 is believed to disclose the cloning of the RIB1 gene coding for the enzyme of the first stage of flavinogenesis in *Pichia guilliermondii* yeast and GTP cyclohydrolase in *E. coli* cells. An English language abstract appears at the end of the article.

Document AT16 is in a foreign language. Document AT16 is believed to disclose the respiration system of *Pichia guilliermondii* yeast at different levels of flavinogenesis. An English language abstract appears at the end of the article.

Document AR17 is in a foreign language. Document AR17 is believed to disclose the respiration system of *Pichia guilliermondii* yeast at different levels of flavinogenesis. An English language abstract appears at the end of the article.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not an issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

This Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this pleading is enclosed.

Respectfully submitted,  
STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

*Michele A. Cimbala*

Michele A. Cimbala  
Attorney for Applicants  
Registration No. 33,851

Date: July 18, 2002  
1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600